UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/619,237	07/14/2003	Jorgen K. Smedegaard	6520.200-US	. 5828	
23650 NOVO NORD	7590 07/06/2007 ISK INC	•	EXAMINER		
PATENT DEPARTMENT			BOUCHELLE, LAURA A		
PRINCETON,	E ROAD WEST NJ 08540		ART UNIT	PAPER NUMBER	
,		•	3763		
		• (2)			
•			NOTIFICATION DATE	DELIVERY MODE	
			07/06/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

nnipatent@novonordisk.com

	-	1		
		Application No.	Applicant(s)	
	Office Action Surrence	10/619,237	SMEDEGAARD,	JORGEN K.
	Office Action Summary	Examiner	Art Unit	
	The MAIL INC DATE of 4 to	Laura A. Bouchelle	3763	
 Period for	The MAILING DATE of this communication app Reply	pears on the cover sheet wit	th the correspondence a	adress
WHICH - Extensi after SI - If NO p - Failure Any rep	RTENED STATUTORY PERIOD FOR REPL' IEVER IS LONGER, FROM THE MAILING Dons of time may be available under the provisions of 37 CFR 1.1 X (6) MONTHS from the mailing date of this communication. eriod for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute by received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 36(a). In no event, however, may a re will apply and will expire SIX (6) MON' e, cause the application to become AB	CATION. apply be timely filed THS from the mailing date of this ANDONED (35 U.S.C. § 133).	
Status				
1)⊠ F	Responsive to communication(s) filed on 12 F	ebruary 2007.		
·		action is non-final.	·	
	Since this application is in condition for allowal losed in accordance with the practice under E			e merits is
Dispositio	n of Claims			
4; 5)□ 0 6)⊠ 0 7)□ 0	Claim(s) 1-18 and 30-34 is/are pending in the a) Of the above claim(s) 1-18 is/are withdrawn claim(s) is/are allowed. Claim(s) 30-34 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/o	n from consideration.		·
Applicatio		r election requirement.		
	he specification is objected to by the Examine	ar.		
•	he drawing(s) filed on is/are: a)☐ acc		by the Examiner.	
-	Applicant may not request that any objection to the		·	
	Replacement drawing sheet(s) including the correct			CFR 1.121(d).
11) 🔲 T	he oath or declaration is objected to by the Ex	xaminer. Note the attached	Office Action or form F	TO-152.
Priority un	nder 35 U.S.C. § 119			
a) <u></u> 1	cknowledgment is made of a claim for foreign All b) Some * c) None of: Certified copies of the priority document Compared to the priority document	ts have been received.		
	B. Copies of the certified copies of the prior application from the International Burea	rity documents have been	• •	ll Stage
* Se	ee the attached detailed Office action for a list		received.	
Attachment(s)			
2) Notice 3) Inform	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date	Paper No(s	Summary (PTO-413) s)/Mail Date nformal Patent Application	

DETAILED ACTION

Claim Objections

1. Claim 30 is objected to because of the following informalities: "disease" is misspelled.

Appropriate correction is required.

Claim Rejections - 35 USC § 102/103

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims 30-34 are rejected under 35 U.S.C. 102(c) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Gross et al (US 5848991). Gross discloses a method of treating a patient with a disease comprising the steps of providing a delivery device having a lower surface with adhesive means adapted to be attached to the skin surface of a patient (Col. 3,

lines 46-47), delivering therapeutic agent to the patient during a period of sleep, removing the

device after the period of sleep (Col. 4, lines 55-65). Gross does not explicitly disclose that the

device delivers fluid for a period of 7-9 hours. However, Gross does disclose that the device

delivers fluid during sleep which is either inherently, or obviously, approximately 7-9 hours.

Gross discloses that the reservoir can hold 0.2-10 mL of fluid which is capable of containing 5-

50 IU of insulin.

Response to Arguments

5. Applicant's arguments filed 2/12/07 have been fully considered but they are not persuasive.

6. Applicant argues that Gross does not teach that the patient has the drug delivery device

attached only during the night. The examiner disagrees. Gross states that the device can be

programmed to meet a dosage regime which will suit the requirements of the individual and the

drug to be delivered. Further, Gross states that the device can take into account periods of sleep,

and a separate device for daytime and nighttime might be provided. It is clear from the

disclosure of Gross that a wide and diverse variety of dosage regimes were contemplated,

including a regime wherein the patient only receives treatment during periods of sleep.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura A. Bouchelle whose telephone number is 571-272-2125. The examiner can normally be reached on Monday-Friday 8-4.

Application/Control Number: 10/619,237

Art Unit: 3763

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Nicholas Lucchesi can be reached on 517-272-4977. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Laura A Bouchelle

Page 4

Examiner

Art Unit 3763

RICHOLAS D. LUCCHESI

ISVINANA TETTA PERMINANT PORE RATHES YOU LOAMORE